

Rifampicin enhanced carbapenem activity with improved antibacterial effects and eradicates established *Acinetobacter baumannii* biofilms.

Lois Chinwe Nwabor¹, Arnon Chukamnerd², Ozioma Forstinus Nwabor², Rattanaruji Pomwised³, Supayang P. Voravuthikunchai^{3,4,5} and Sarunyou Chusri^{1,2} *




Figure S1: The distribution of rifampicin resistant *Acinetobacter baumannii* clinical isolates. CLSI interpretation criteria for *Staphylococcus aureus* * susceptible ≥ 20 * intermediate 17-19* Resistant ≤ 16




Figure S2: Time-kill kinetic of rifampicin and combination with meropenem against rifampicin resistant and carbapenem resistant clinical isolate of *A. baumannii* SK024. Experiments were performed in duplicate.




Figure S3. Cell viability of monotherapy against 96 h established biofilm (A) TR069 (B) ST004 and (C) ATCC 19606 expressed as percentage viability. MIC, minimum inhibitory concentration; RIF, rifampicin; MEM, meropenem; DOR, doripenem; IMP, imipenem. * $P < 0.05$




Figure S4. Cell viability of combination therapy against 96 h established biofilm (A) TR069 (B) ST004 and (C) ATCC 19606 expressed as percentage viability. MIC, minimum inhibitory concentration; RIF, rifampicin; MEM, meropenem; DOR, doripenem; IMP, imipenem. * $P < 0.05$